Abstract
Nanomedicine contributes exceptional possibilities for novel therapeutic management. Nanomedicine moderately interlocks, exceeds, and overlaps other medical curriculum. As various approaches in Nanomedicine had progressed with enormous promise toward theranostic interventions, ethical queries also arise in conjunction. Nanomedicine is a unique niche in various facets, but it comes along with indications of dangers and uncertainties not confronted in other fields of medical practice or analysis. Some intellectuals agree that progress in the field of nanotechnology may present several ethical challenges, while others dispute that these challenges are not recent and that nanotechnology generally echoes frequent bioethical impasses. The objective of this article is to analyze some of the ethical concerns associated with Nanomedicine application and to reveal the queries and recent developments on whether Nanomedicine yields further ethical challenges keeping in view the principle of medical ethics. Such a conclusion should have significance on professional strategy and regulatory approaches and designing the policies for application in the upcoming days.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allon I, Ben-Yehudah A, Dekel R, Solbakk JH, Weltring KM, Siegal G (2017) Ethical issues in nanomedicine: tempest in a teapot? Medicine. Health Care Philos 20(1):3–1
Bawa R (2005) Will the nanomedicine “patent land grab” thwart commercialization? Nanomedicine: nanotechnology. Biol Med 1(4):346–340
Bawa R, Johnson S (2007) The ethical dimensions of nanomedicine. Med Clin N Am 91(5):881–887
Bawa R, Johnson S (2009) Emerging issues in nanomedicine and ethics. In: Nanotechnology & society. Springer, Dordrecht, pp 207–203
Bawa R, Bawa SR, Maebius SB, Flynn T, Wei C (2005) Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 1(2):150–158
Bruce D (2006) The question of ethics. Nano Today 1(1):6–7
Chang EH, Harford JB, Eaton MA, Boisseau PM, Dube A, Hayeshi R et al (2015) Nanomedicine: past, present and future–a global perspective. Biochem Biophys Res Commun 468(3):511–517
de SC, Nigel M (2006) The NELSI imperative: nano ethical, legal and social issues, and federal policy development. Nanotechnol Law Bus 3:159
Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14(2):282–285
Dresser R (2012) Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 40(4):802–808
Ebbesen M (2008) The role of the humanities and social sciences in nanotechnology research and development. NanoEthics 2(1):1–3
Ebbesen M, Andersen S, Besenbacher F (2006) Ethics in nanotechnology: starting from scratch? Bull Sci Technol Soc 26(6):451–452
Ferrari M, Philibert MA, Sanhai WR (2009) Nanomedicine and society. Clin Pharmacol Ther 85(5):466–467
Gelfert A (2012) Nanotechnology as ideology: towards a critical theory of ‘converging technologies’. Sci Technol Soc 17(1):143–144
Gökçay B, Berna AR (2015) Nanotechnology, nanomedicine; ethical aspects. Rev Romana Bioet 13(3):423–432
Graur F, Elisei R, Szasz A, Neagos HC, Muresan A, Furcea L et al (2011) Ethical issues in nanomedicine. In: International conference on advancements of medicine and health care through technology. Springer, Cham, pp 9–12
Habets MG, van Delden JJ, Bredenoord AL (2016) Studying the lay of the land: views and experiences of professionals in the translational pluripotent stem cell field. Regen Med 11(1):63–61
Hall RM, Sun T, Ferrari M (2012) A portrait of nanomedicine and its bioethical implications. J Law Med Ethics 40(4):763–769
Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E et al (2013) Managing data quality for a drug safety surveillance system. Drug Saf 36(1):49–48
Anderson JA, Kimmelman J (2010) Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst Ethics J 20(1):75–98
Hogle LF (2012) Concepts of risk in nanomedicine research. J Law Med Ethics 40(4):809–802
Jamison A (2009) Can nanotechnology be just? On nanotechnology and the emerging movement for global justice. NanoEthics 3(2):129–126
Jotterand F (ed) (2008) Emerging conceptual, ethical and policy issues in bionanotechnology. Springer, Dordrecht
Kearnes M (2006) Chaos and control: nanotechnology and the politics of emergence. Paragraph 29(2):57–50
Keiper A (2007) Nanoethics as a discipline? The New Atlantis 16:55–57
Kuiken T (2011) Nanomedicine and ethics: is there anything new or unique? Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(2):111–118
Leary JF (2013) Nanomedicine–reality will trump hype! J Nanomed Biother Discov 4:125
Liu D, Yang F, Xiong F, Gu N (2016) The smart drug delivery system and its clinical potential. Theranostics 6(9):1306
Nel A, Xia T, Mädler L, Li N (2006) Toxic potential of materials at the nanolevel. Science 311(5761):622–627
Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K et al (2005a) Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2(1):8
Oberdörster G, Oberdörster E, Oberdörster J (2005b) Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113(7):823–829
Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19(12):1584
Patra D, Haribabu E, McComas KA (2010) Perceptions of nano ethics among practitioners in a developing country: a case of India. NanoEthics 4(1):67–65
Resnik DB, Tinkle SS (2007) Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials 28(4):433–431
Sandler R (2009) Nanomedicine and nanomedical ethics. Am J Bioeth 9(10):16–17
Satalkar P, Elger BS, Shaw DM (2016) Defining nano, nanotechnology and nanomedicine: why should it matter? Sci Eng Ethics 22(5):1255–1256
Schottel BL, Karn B (2016) The national nanotechnology initiative approach to environment, health, and safety: a model for future science investments. Fed Hist 8:48
Sechi G, Bedognetti D, Sgarrella F, Eperen LV, Marincola FM, Bianco A et al (2014) The perception of nanotechnology and nanomedicine: a worldwide social media study. Nanomedicine 9(10):1475–1476
Sharma R, Mody N, Agrawal U, Vyas SP (2017) Theranostic nanomedicine; a next generation platform for cancer diagnosis and therapy. Mini Rev Med Chem 17(18):1746–1747
Siddique S, Alexander A, Yadav P, Agrawal M, Shehata AM, Shaker MA et al (2019) Nanomedicines: challenges and perspectives for future nanotechnology in the healthcare system. Sci Res Essays 14(5):32–38
Solbakk JH, Zoloth L (2011) The tragedy of translation: the case of “first use” in human embryonic stem cell research. Cell Stem Cell 8(5):479–471
Strom BL (2006) How the US drug safety system should be changed. JAMA 295(17):2072–2075
Turanlı ET, Everest E (2016) Nanomedicine. In: Low-dimensional and nanostructured materials and devices. Springer, Cham, pp 579–587
Ventola CL (2012a) The nanomedicine revolution: part 1: emerging concepts. Pharm Ther 37(9):512
Ventola CL (2012b) The nanomedicine revolution: part 3: regulatory and safety challenges. Pharm Ther 37(11):631
Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther 42(12):742
Wolf SM, Jones CM (2011) Designing oversight for nanomedicine research in human subjects: systematic analysis of exceptional oversight for emerging technologies. J Nanopart Res 13(4):1449–1445
Wynne B (1992) Uncertainty and environmental learning: reconceiving science and policy in the preventive paradigm. Glob Environ Chang 2(2):111–117
Yeagle J (2007) Nanotechnology and the FDA. VA J Law Technol 12:1
Życiński J (2006) Ethics in medical technologies: the Roman Catholic viewpoint. J Clin Neurosci 13(5):518–513
Acknowledgement
The authors are thankful to Chettinad Academy of Research and Education (CARE) for providing the infrastructural support and to SERB, DST, Govt. of India, for providing the financial support to complete this piece of work.
Author Contribution
The idea and design of the study was conceived by Antara Banerjee. Alakesh Das, Dikshita Deka, Syed Sana Abrar, Surajit Pathak, and Antara Banerjee wrote the manuscript and designed the diagrammatic representations. All the authors read and approved the final version of the manuscript.
Funding
This work was supported by the grants sanctioned to Dr. Antara Banerjee (PI) from the SERB-DST, Govt. of India with the sanction file no ECR/2017/001066 and departmental grants at CARE.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Das, A., Deka, D., Abrar, S.S., Pathak, S., Banerjee, A. (2021). Ethics in Nanomedicine. In: Malik, A., Afaq, S., Tarique, M. (eds) Nanomedicine for Cancer Diagnosis and Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-15-7564-8_9
Download citation
DOI: https://doi.org/10.1007/978-981-15-7564-8_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-7563-1
Online ISBN: 978-981-15-7564-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)